Societal CDMO, Inc. - Common Stock (NQ:SCTL)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Societal CDMO, Inc. - Common Stock

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 28, 2023

Via Benzinga

Crude Oil Edges Lower; Dollar Tree Earnings Top Estimates ↗

August 24, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 250 points on Thursday. The Dow traded down 0.75% to 34,212.95 while the NASDAQ fell 1.11% to 13,568.87. The S&P...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 24, 2023

Via Benzinga

US Stocks Turn Lower; Nasdaq Down Over 1% ↗

August 24, 2023

U.S. stocks turned lower midway through trading, with the Dow Jones falling more than 200 points on Thursday. The Dow traded down 0.60% to 34,265.04 while the NASDAQ fell 1.35% to 13,535.36. The S&P...

Via Benzinga

Topics Stocks

A Preview Of Societal CDMO's Earnings ↗

August 11, 2023

Via Benzinga

Societal CDMO's Earnings Outlook ↗

August 08, 2023

Via Benzinga

Societal CDMO: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Societal CDMO Earnings Preview ↗

February 28, 2023

Via Benzinga

Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

August 24, 2023

Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847.

Via Benzinga

Dow Jumps 150 Points; NVIDIA Tops Q2 Views ↗

August 24, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 150 points on Thursday. Following the market opening Thursday, the Dow traded up 0.48% to 34,638.62 while the NASDAQ rose...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 24, 2023

Via Benzinga

Societal CDMO's Return On Capital Employed Insights ↗

December 14, 2022

Via Benzinga

Why Opera Shares Are Trading Lower By Around 12%; Here Are 20 Stocks Moving Premarket ↗

August 24, 2023

Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares gained 45.1% to $2.51 in pre-market trading after falling 50% on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 23, 2023

Via Benzinga

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO's Q2 2023 ↗

August 16, 2023

Societal CDMO Inc. (NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics,...

Via Benzinga

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

Innovator Embraces Psychedelic Horizons With New Schedule 1 Manufacturing License ↗

July 27, 2023

A new player is entering the psychedelics production space.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 07, 2023

Via Benzinga

Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗

May 24, 2023

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 24, 2023

It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning!

Via InvestorPlace

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 03, 2023

Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program

From Cingulate Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗

March 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 12, 2022

Via Benzinga

A Preview Of Societal CDMO's Earnings ↗

November 08, 2022

Societal CDMO (NASDAQ:SCTL) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Societal...

Via Benzinga

Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD ↗

October 25, 2022

Cingulate Inc (NASDAQ: CING) is preparing to initiate a Phase 3 adult dose-optimization study later this year for its lead candidate, CTx-1301, to assess the onset and duration of efficacy and safety...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 16, 2022

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.